|
Birth Weight
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Maternal and fetal genetic effects on birth weight and their relevance to cardio-metabolic risk factors.
|
31043758 |
2019 |
|
Blepharoptosis
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Body Height
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Body mass index
|
0.100 |
GeneticVariation
|
phenotype |
GWASDB |
A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance.
|
22581228 |
2012 |
|
Body mass index
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genome-wide association study identifies 112 new loci for body mass index in the Japanese population.
|
28892062 |
2017 |
|
Body mass index
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance.
|
22581228 |
2012 |
|
Carcinogenesis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Recent investigation of somatic variations of allosterically regulated proteins in cancer genomes suggested that variations in glucokinase (GCK) might play a role in tumorigenesis.
|
30590153 |
2019 |
|
Carcinogenesis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Due to the inhibitory function of HPK1/MAP4K1 in T-cell activation and the promoting effects of GLK on tumorigenesis, HPK1 and GLK dual inhibitors could be useful therapeutic drugs for cancer immunotherapy.
|
31640697 |
2019 |
|
Carcinoma of lung
|
0.020 |
Biomarker
|
disease |
BEFREE |
Collectively, GLK promotes lung cancer metastasis by binding to, phosphorylating, and activating IQGAP1.
|
31431460 |
2019 |
|
Carcinoma of lung
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
In addition, GLK overexpression in cancer tissues is correlated with cancer recurrence of human lung cancer and liver cancer; the predictive power of GLK overexpression for cancer recurrence is higher than that of pathologic stage.
|
31640697 |
2019 |
|
Cardiovascular Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
Elucidating the molecular basis of ligand-mediated control over the GCK-GKRP interaction is expected to impact the development and future refinement of therapeutic agents for diabetes and cardiovascular disease, which result from improper GKRP regulation of GCK.
|
28516783 |
2017 |
|
Caudal Regression Syndrome
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
This case raises the question as to whether hyperglycaemia in GCK-MODY may increase the risk of fetal caudal regression syndrome as reported in women with pre-existing diabetes mellitus.
|
30362177 |
2019 |
|
Chagas Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
Glucokinase and hexokinase from pathogenic protozoa Trypanosoma cruzi are potential drug targets for antiparasitic chemotherapy of Chagas' disease.
|
26778112 |
2015 |
|
Channelopathies
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
In contrast to focal islet-cell hyperplasia, always sporadic to our knowledge, diffuse hyperinsulinism is a heterogeneous disorder involving several genes, various mechanisms of pathogenic mutations and different transmissions: (i) channelopathy involving the genes encoding the sulphonylurea receptor (SUR1) or the inward-rectifying potassium channel (Kir6.2) in recessively inherited HI or more rarely dominantly inherited HI; (ii) metabolic disorders implicating the short-chain L-3-hydroxyacyl-CoA dehydrogenase (SCHAD) enzyme inrecessively inherited HI, the glucokinase gene (GK), the glutamate dehydrogenase gene (GLUD1) when hyperammonemia is associated, dominant exercise-induced HI with still-unknown mechanism, and more recently the human insulin receptor gene in dominantly inherited hyperinsulinism.
|
15868462 |
2005 |
|
Channelopathies
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
The major causes are channelopathies, the other forms are rare and being caused by mutations in genes such as GCK.
|
28247534 |
2017 |
|
Channelopathies
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
This can manifest as 'channelopathies' of K(ATP) channels through gene defects in ABCC8 and KCNJ11 (Ch.11p15); or as a result of 'metabolopathies' through defects in the genes encoding glucokinase (GCK, Ch.7p15-p13), glutamate dehydrogenase (GLUD1, Ch.10q23.3) and short-chain L-3-hydroxyacyl-CoA dehydrogenase (HADHSC, Ch.4q22-q26).
|
14981344 |
2004 |
|
Chronic Kidney Diseases
|
0.020 |
Biomarker
|
group |
BEFREE |
To clarify the association of glucokinase and glucokinase regulatory protein (GCKR) polymorphisms with the risk of CKD in Japan, we examined this association among Japanese individuals using cross-sectional data.
|
24535998 |
2014 |
|
Chronic Kidney Diseases
|
0.020 |
Biomarker
|
group |
BEFREE |
Effect of Hepatic Organic Anion-Transporting Polypeptide 1B Inhibition and Chronic Kidney Disease on the Pharmacokinetics of a Liver-Targeted Glucokinase Activator: A Model-Based Evaluation.
|
30919935 |
2019 |
|
Cirrhosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Hexokinase isoenzymes in normal and cirrhotic human liver: suppression of glucokinase in cirrhosis.
|
9468341 |
1998 |
|
Clinodactyly
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Clinodactyly of fingers
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Clumsiness - motor delay
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Comatose
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Complications of Diabetes Mellitus
|
0.010 |
GeneticVariation
|
group |
BEFREE |
To assess the prevalence of diabetes complications and the severity of diabetes in kindreds with NIDDM linked to the MODY3 locus (chromosome 12q) and to compare these parameters with data obtained in glucokinase (GCK)-deficient and other-MODY (unlinked to any of the three known loci) families, as well as with data from families with a late age of onset of NIDDM.
|
8875082 |
1996 |
|
Congenital Abnormality
|
0.010 |
Biomarker
|
group |
BEFREE |
The association between GCK-MODY and congenital abnormalities, however, remains uncertain.
|
30362177 |
2019 |